News Novartis AG

Equities

NOVN

CH0012005267

Market Closed - Swiss Exchange Other stock markets 11:31:51 2024-04-24 am EDT			5-day change	1st Jan Change
89.12 ^CHF	+0.20%		+5.03%	+5.01%

05:22pm	BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating	MT
04:55pm	Novartis Says New Malaria Drug Formulation Safe and Effective for Babies	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating	11:22am	MT
Novartis Says New Malaria Drug Formulation Safe and Effective for Babies	10:55am	MT
Dpa-AFX Overview: COMPANIES from 24.04.2024 - 15:15	09:20am	DP
NOVARTIS AG : UBS reaffirms its Buy rating	07:56am	ZD
NOVARTIS AG : Deutsche Bank gives a Buy rating	07:22am	ZD
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	06:45am	RE
Novartis: positive data for malaria treatment	04:18am	CF
NOVARTIS AG : JP Morgan remains Neutral	03:26am	ZD
Novartis, Medicines for Malaria Say Treatment for Babies Shows Efficacy	01:35am	DJ
Novartis Partnership Says New Malaria Drug for Babies Effective, Safe in Phase 2/3 Trial	01:20am	MT
Novartis Faces Lawsuit for Illegal Promotion of Asthma Drug as Preterm Labor Treatment	12:42am	MT
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria	12:30am	GL
Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies	12:30am	CI
Novartis Receives FDA Approval for Gastroenteropancreatic Tumor Treatment in Pediatric Patients	11:54pm	MT
Novartis, Danaher rise; Nucor, Cadence Design Systems fall, Tuesday, 4/23/2024	Apr. 23	AQ
US Equity Markets Close Higher Tuesday	Apr. 23	MT
Novartis Wins FDA Approval of Pancreatic Tumor Therapy in Children	Apr. 23	MT
Novartis Gets FDA Approval for Lutathera in Pediatric Treatment	Apr. 23	DJ
Novartis radioligand therapy Lutathera(R) FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	Apr. 23	DJ
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	Apr. 23	GL